Published on

Medicine – Antiviral Drugs (Non-HIV): Classification, Mechanisms of Action, Clinical Uses and Adverse Effects

1. Introduction to Antiviral Drugs

Antiviral drugs are medications used to prevent or treat infections caused by viruses. Unlike bacteria, viruses are obligate intracellular pathogens that depend on host cells for replication. Consequently, antiviral medications target specific stages of the viral replication cycle, including viral entry, nucleic acid synthesis, genome replication, protein processing and release of newly formed viral particles.

The antiviral drugs discussed in the original notes are aciclovir, ganciclovir and ribavirin. Aciclovir is particularly important for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, while ganciclovir has a major role in cytomegalovirus (CMV) infections. Ribavirin has historically been used against hepatitis C virus (HCV), respiratory syncytial virus (RSV) and Lassa fever virus.

Modern antiviral therapy also includes several additional agents, such as valaciclovir, valganciclovir, foscarnet, oseltamivir, baloxavir, direct-acting antivirals for hepatitis C and antiviral drugs for hepatitis B. These medications differ in their viral targets, clinical indications, adverse effects and resistance profiles.

2. Classification of Non-HIV Antiviral Drugs

Non-HIV antiviral drugs can be classified according to the viruses they treat and their mechanisms of action.

Anti-herpesvirus drugs include aciclovir, valaciclovir, famciclovir, ganciclovir, valganciclovir, foscarnet and cidofovir. These medications primarily interfere with viral DNA replication and are used against selected members of the herpesvirus family.

Anti-influenza drugs include oseltamivir, zanamivir, peramivir and baloxavir. These drugs inhibit viral neuraminidase or viral RNA transcription.

Anti-hepatitis drugs include nucleoside or nucleotide analogues for hepatitis B and direct-acting antiviral combinations for hepatitis C.

Other antiviral drugs, including ribavirin and remdesivir, act on viral RNA synthesis or replication and have specific clinical indications.

The choice of treatment depends on the virus, severity of infection, immune status and organ function.

3. Aciclovir

Aciclovir, also spelled acyclovir, is a guanosine nucleoside analogue used mainly to treat infections caused by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV).

Aciclovir is particularly effective against HSV because infected cells contain viral thymidine kinase, which activates the drug. This allows aciclovir to act selectively within infected cells while producing relatively limited toxicity in uninfected tissues.

It is available in oral, intravenous and topical formulations. The appropriate route depends on the severity and location of infection.

4. Mechanism of Action of Aciclovir

Aciclovir initially enters infected cells in an inactive form. Viral thymidine kinase converts it into aciclovir monophosphate, after which host cellular enzymes convert it into the active triphosphate form.

Aciclovir triphosphate inhibits viral DNA polymerase and becomes incorporated into newly synthesised viral DNA. Because aciclovir lacks the normal chemical structure required for continued DNA elongation, it causes premature termination of viral DNA synthesis.

This prevents effective replication of HSV and VZV.

The selective activation of aciclovir by viral thymidine kinase explains its relatively favourable therapeutic index.

5. Aciclovir in Herpes Simplex Virus Infection

HSV-1 and HSV-2 cause a variety of infections involving the skin, mucous membranes, eyes and nervous system.

HSV-1 is classically associated with orolabial herpes, while HSV-2 is strongly associated with genital herpes. However, either virus can infect oral or genital sites.

Aciclovir is used to treat primary and recurrent mucocutaneous HSV infections. Treatment can reduce symptom duration, viral shedding and the frequency of recurrences when suppressive therapy is used.

Aciclovir does not eliminate latent HSV infection from sensory ganglia. Therefore, recurrent episodes may still occur after treatment.

6. Aciclovir in Herpes Simplex Encephalitis

One of the most important indications for intravenous aciclovir is herpes simplex encephalitis.

HSV encephalitis is a potentially life-threatening infection of the brain, classically associated with inflammation involving the temporal lobes.

Patients may present with fever, headache, confusion, seizures, behavioural changes and focal neurological deficits.

Because untreated HSV encephalitis can cause severe neurological damage or death, intravenous aciclovir should be started promptly when HSV encephalitis is strongly suspected, without waiting for definitive laboratory confirmation.

Diagnosis is supported by cerebrospinal fluid HSV PCR and appropriate neuroimaging.

7. Aciclovir in Varicella-Zoster Virus Infection

Varicella-zoster virus causes two major clinical syndromes: varicella (chickenpox) and herpes zoster (shingles).

Primary VZV infection causes chickenpox, whereas reactivation of latent virus in sensory ganglia produces shingles.

Aciclovir can be used in selected patients with chickenpox, particularly those at increased risk of complications. It is also used for herpes zoster, especially in older adults, immunocompromised patients and individuals with severe disease.

Early antiviral treatment of shingles reduces viral replication and can accelerate lesion healing and resolution of acute symptoms.

8. Aciclovir in Disseminated VZV Infection

Severe VZV infection can occur in immunocompromised patients and may involve the lungs, liver, brain or multiple organ systems.

Disseminated varicella, VZV encephalitis and other severe complications generally require intravenous aciclovir.

Prompt treatment is important because uncontrolled viral replication can cause serious tissue injury.

The intravenous route provides higher and more reliable systemic concentrations than oral treatment.

9. Valaciclovir

Valaciclovir is an oral prodrug of aciclovir. After absorption, it is converted into aciclovir.

Its major advantage is better oral bioavailability, allowing more convenient dosing than oral aciclovir.

Valaciclovir is commonly used for oral herpes, genital herpes and shingles. It can also be used for suppressive treatment of recurrent genital herpes.

Although valaciclovir and aciclovir have similar antiviral activity after conversion, severe infections such as HSV encephalitis generally require intravenous aciclovir rather than routine oral valaciclovir treatment.

10. Adverse Effects of Aciclovir

Aciclovir is generally well tolerated, particularly when administered orally.

Common adverse effects include nausea, headache and gastrointestinal discomfort.

An important complication of intravenous aciclovir is acute kidney injury, which may occur because of precipitation of aciclovir crystals within renal tubules or other mechanisms of renal toxicity.

Adequate hydration, appropriate infusion rates and renal dose adjustment help reduce this risk.

Aciclovir can also cause neurotoxicity, particularly in patients with renal impairment. Manifestations may include confusion, hallucinations, tremor or seizures.

11. Resistance to Aciclovir

Aciclovir resistance occurs most commonly through mutations affecting viral thymidine kinase, preventing effective activation of the drug.

Resistance may also arise through alterations in viral DNA polymerase.

Aciclovir-resistant HSV infection is particularly important in severely immunocompromised patients.

Because foscarnet does not require activation by viral thymidine kinase, it is an important treatment option for aciclovir-resistant HSV infections.

12. Ganciclovir

Ganciclovir is a guanosine nucleoside analogue structurally related to aciclovir.

The original notes correctly state that ganciclovir has activity against HSV and VZV, but its most important clinical role is the treatment and prevention of cytomegalovirus (CMV) infection.

Ganciclovir is more active against CMV than aciclovir and is commonly used in immunocompromised patients, including transplant recipients and individuals with advanced immunosuppression.

However, ganciclovir is not routinely preferred over aciclovir or valaciclovir for uncomplicated HSV or VZV infections because of its greater toxicity.

13. Mechanism of Action of Ganciclovir

Ganciclovir inhibits viral DNA synthesis after intracellular activation.

In CMV-infected cells, the viral UL97 protein kinase is responsible for the initial phosphorylation of ganciclovir.

Host cellular enzymes then convert it into ganciclovir triphosphate.

The active metabolite inhibits viral DNA polymerase and interferes with viral DNA elongation.

This suppresses CMV replication and limits progression of infection.

14. Cytomegalovirus Infection

CMV belongs to the herpesvirus family and establishes lifelong latent infection after primary exposure.

In immunocompetent individuals, CMV infection is often asymptomatic or produces a mononucleosis-like illness.

However, in immunocompromised patients, CMV can reactivate and cause severe organ disease.

Important manifestations include CMV retinitis, colitis, oesophagitis, pneumonitis and other tissue-invasive infections.

CMV is particularly important after solid-organ or haematopoietic stem-cell transplantation.

15. Ganciclovir in CMV Retinitis

CMV retinitis is a serious opportunistic infection that may occur in patients with profound immunosuppression, particularly advanced HIV infection.

The infection causes retinal inflammation and necrosis, which may progress to visual loss if untreated.

Systemic valganciclovir or intravenous ganciclovir may be used depending on disease severity, immune status and the patient’s ability to tolerate oral medication.

Sight-threatening lesions may require additional intravitreal treatment under specialist care.

The key association is CMV retinitis treated with ganciclovir or valganciclovir.

16. Ganciclovir in Transplant Recipients

CMV is an important cause of infection and complications after organ transplantation.

Immunosuppressive treatment reduces the ability of the immune system to control CMV replication, increasing the risk of viral reactivation or newly acquired infection.

Ganciclovir and valganciclovir are used for treatment and, in appropriate patients, prevention of CMV disease.

Treatment decisions depend on the type of transplant, donor and recipient CMV serostatus, degree of immunosuppression, viral load and clinical manifestations.

17. Valganciclovir

Valganciclovir is an oral prodrug of ganciclovir with substantially improved oral absorption.

After administration, it is converted into ganciclovir.

Valganciclovir is widely used for CMV prophylaxis and treatment in appropriate patients, particularly transplant recipients.

Its major advantage is that it provides effective systemic ganciclovir exposure through oral administration.

However, valganciclovir shares many of the important toxicities of ganciclovir, including bone marrow suppression.

18. Adverse Effects of Ganciclovir

The most important adverse effect of ganciclovir is bone marrow suppression.

This may produce neutropenia, anaemia and thrombocytopenia.

Neutropenia is particularly important in transplant recipients and other immunocompromised patients because it increases susceptibility to bacterial and fungal infections.

Ganciclovir may also cause gastrointestinal disturbances and renal-related toxicity concerns. Because the drug is eliminated predominantly through the kidneys, dose adjustment is necessary in renal impairment.

Patients receiving treatment generally require monitoring of full blood count and renal function.

19. Ganciclovir Resistance

CMV resistance to ganciclovir commonly involves mutations in the viral UL97 kinase, reducing activation of the drug.

Mutations involving the viral DNA polymerase gene, UL54, may also contribute to resistance.

Resistant CMV infection is particularly important in transplant recipients who require prolonged antiviral treatment.

Alternative agents may include foscarnet, cidofovir or maribavir in selected circumstances, depending on resistance patterns, disease severity and clinical guidance.

20. Foscarnet

Foscarnet is an antiviral medication that directly inhibits viral DNA polymerase.

Unlike aciclovir and ganciclovir, foscarnet does not require activation by viral kinases.

This makes it useful against selected viral strains that have developed resistance through defective viral drug phosphorylation.

Foscarnet may be used for aciclovir-resistant HSV infections and selected ganciclovir-resistant CMV infections.

Its major limitation is toxicity, particularly nephrotoxicity and disturbances in calcium, magnesium, potassium and phosphate concentrations.

21. Cidofovir

Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase after activation by host cellular enzymes.

It does not require initial phosphorylation by viral thymidine kinase or CMV UL97 kinase.

Cidofovir has activity against several DNA viruses and may be used in selected resistant CMV infections.

However, its clinical use is limited by substantial nephrotoxicity.

Intravenous cidofovir requires specialised precautions, including appropriate hydration and probenecid administration in relevant treatment regimens.

22. Ribavirin

Ribavirin is a synthetic guanosine analogue with broad antiviral activity against several RNA viruses.

The original notes identify three important historical or selected clinical associations: hepatitis C virus, respiratory syncytial virus and Lassa fever virus.

Ribavirin interferes with viral replication through several mechanisms, including effects on nucleotide availability and viral RNA synthesis.

Its antiviral effects vary between viruses, and its clinical usefulness depends on the specific infection.

An important modern distinction is that ribavirin is no longer a routine component of treatment for most hepatitis C infections because highly effective direct-acting antivirals are now available.

23. Mechanism of Action of Ribavirin

Ribavirin undergoes intracellular phosphorylation to produce active metabolites.

One important mechanism involves inhibition of inosine monophosphate dehydrogenase, which reduces intracellular guanosine nucleotide availability.

Ribavirin can also interfere with viral RNA synthesis and may increase the frequency of mutations during viral genome replication in susceptible viruses.

These mechanisms contribute to its broad antiviral activity, although their relative importance differs between infections.

24. Ribavirin in Hepatitis C

Ribavirin was historically used in combination with interferon or pegylated interferon for the treatment of chronic hepatitis C.

These older regimens required prolonged treatment and were associated with substantial adverse effects.

Modern hepatitis C treatment relies primarily on direct-acting antiviral combinations, which target specific HCV proteins involved in replication.

Ribavirin still has a role in selected difficult-to-treat situations, such as certain retreatment regimens or patients with decompensated cirrhosis, but it is not routinely required for most patients.

Therefore, the original association between ribavirin and HCV is historically correct but requires updating.

25. Direct-Acting Antivirals for Hepatitis C

Direct-acting antivirals have transformed the treatment of hepatitis C because they achieve very high cure rates with relatively short treatment courses.

These medications target specific HCV proteins, including NS3/4A protease, NS5A and NS5B polymerase.

Examples include sofosbuvir, velpatasvir, glecaprevir and pibrentasvir.

Common pangenotypic combinations include sofosbuvir/velpatasvir and glecaprevir/pibrentasvir.

Treatment selection depends on factors such as cirrhosis status, previous antiviral treatment, drug interactions and renal or hepatic function.

26. Ribavirin in Respiratory Syncytial Virus Infection

Respiratory syncytial virus is an important cause of lower respiratory tract infection, particularly in infants, older adults and immunocompromised individuals.

RSV commonly causes bronchiolitis in young children and may also cause pneumonia.

Ribavirin has antiviral activity against RSV and has been used in aerosolised or systemic formulations in selected circumstances.

However, ribavirin is not routinely recommended for otherwise healthy infants with RSV bronchiolitis.

Management of uncomplicated RSV bronchiolitis is mainly supportive, including appropriate oxygen therapy, hydration and respiratory monitoring when necessary.

Ribavirin may be considered in selected severely immunocompromised patients under specialist guidance.

27. Ribavirin in Lassa Fever

Lassa fever is a viral haemorrhagic fever caused by Lassa virus, an arenavirus endemic in parts of West Africa.

The infection may range from mild febrile illness to severe systemic disease with bleeding, organ dysfunction and shock.

Ribavirin has historically been used as antiviral treatment, particularly when administered early in the illness.

However, the quality of evidence supporting its effectiveness is limited and debated, and optimal treatment protocols remain an area of clinical uncertainty.

Management also requires intensive supportive care, infection prevention measures and specialist infectious disease expertise.

28. Adverse Effects of Ribavirin

The most important adverse effect of ribavirin is haemolytic anaemia.

Ribavirin can accumulate within erythrocytes and contribute to oxidative injury and red blood cell destruction.

This may produce fatigue, pallor and worsening anaemia, particularly in patients with underlying cardiovascular disease.

Other adverse effects include gastrointestinal symptoms, rash and fatigue.

Ribavirin is also embryotoxic and teratogenic and must be avoided during pregnancy. Strict pregnancy-prevention precautions are required during treatment and for the recommended period after treatment, according to the relevant product guidance.

29. Antiviral Drugs for Influenza

Influenza is caused mainly by influenza A and influenza B viruses.

Antiviral treatment is particularly important in patients with severe disease, hospitalisation or increased risk of complications.

The principal antiviral medications include oseltamivir, zanamivir, peramivir and baloxavir.

Treatment is generally most effective when started early, although patients with severe or progressive influenza may benefit from antiviral treatment even when presentation occurs later.

30. Oseltamivir

Oseltamivir is an oral neuraminidase inhibitor active against influenza A and B.

Neuraminidase is a viral enzyme involved in the release of newly formed influenza particles from infected respiratory epithelial cells.

By inhibiting neuraminidase, oseltamivir reduces viral spread within the respiratory tract.

It is commonly used for influenza treatment in patients at increased risk of complications and in those with severe or hospitalised influenza.

Common adverse effects include nausea and vomiting.

31. Zanamivir and Peramivir

Zanamivir and peramivir are additional neuraminidase inhibitors.

Zanamivir is administered by inhalation and has activity against influenza A and B. Because inhaled zanamivir may cause bronchospasm, it is generally avoided in patients with underlying airway disease such as asthma or chronic obstructive pulmonary disease.

Peramivir is administered intravenously and may be used in selected influenza cases when appropriate.

Both medications inhibit viral neuraminidase and interfere with the release of newly formed influenza virions.

32. Baloxavir

Baloxavir marboxil is an antiviral drug used for selected influenza infections.

It inhibits the cap-dependent endonuclease activity of the influenza viral polymerase complex, thereby interfering with viral mRNA transcription.

Unlike oseltamivir, which inhibits viral release, baloxavir acts earlier in the viral replication process.

Baloxavir can be administered as a single oral dose in appropriate patients with uncomplicated influenza.

However, its suitability depends on patient characteristics, disease severity and current treatment recommendations.

33. Antiviral Drugs for Hepatitis B

Chronic hepatitis B infection can cause progressive liver inflammation, cirrhosis and hepatocellular carcinoma.

Antiviral therapy suppresses viral replication and reduces the risk of disease progression.

Important medications include tenofovir and entecavir, which inhibit hepatitis B viral reverse transcriptase/DNA polymerase.

These drugs are commonly used as long-term suppressive therapy in patients who meet treatment criteria.

Unlike hepatitis C, hepatitis B is not usually eradicated by currently available nucleoside or nucleotide analogue therapy because viral genetic material can persist within hepatocytes.

34. Antiviral Drugs for COVID-19

SARS-CoV-2 is an RNA virus responsible for COVID-19.

Antiviral treatment may be appropriate in selected patients, particularly those at increased risk of severe disease.

Important agents include nirmatrelvir/ritonavir and remdesivir.

Nirmatrelvir inhibits the SARS-CoV-2 main protease, while ritonavir increases nirmatrelvir exposure by inhibiting its metabolism.

Remdesivir is a nucleotide analogue that inhibits viral RNA-dependent RNA polymerase.

Treatment choice depends on timing, severity, kidney and liver function, medication interactions and patient-specific risk factors.

35. Antiviral Drugs and Renal Function

Renal function is particularly important when prescribing several antiviral medications.

Aciclovir, ganciclovir, valganciclovir and foscarnet may require dose adjustment or careful monitoring in patients with renal impairment.

Aciclovir can cause crystal-associated kidney injury, while foscarnet and cidofovir are associated with substantial nephrotoxicity.

Ganciclovir accumulation can increase the risk of bone marrow suppression.

Therefore, assessment of renal function is an important component of safe antiviral prescribing.

36. Important Adverse Effects – Note Form

Aciclovir may cause nausea, headache, acute kidney injury and neurotoxicity, particularly with intravenous treatment or impaired renal function.

Valaciclovir has similar potential adverse effects because it is converted into aciclovir.

Ganciclovir and valganciclovir are particularly associated with bone marrow suppression, including neutropenia, anaemia and thrombocytopenia.

Foscarnet may cause nephrotoxicity and electrolyte disturbances, including abnormalities of calcium, magnesium, potassium and phosphate.

Cidofovir is strongly associated with nephrotoxicity.

Ribavirin may cause haemolytic anaemia and is teratogenic.

Oseltamivir commonly causes nausea and vomiting.

Zanamivir may precipitate bronchospasm in susceptible patients.

Hepatitis C direct-acting antivirals are generally well tolerated, but drug interactions and liver disease severity must be considered.

37. Important Corrections to the Original Notes

The original statement that aciclovir is active against HSV and VZV is correct. Aciclovir is particularly important for mucocutaneous HSV infections, herpes zoster and severe infections such as HSV encephalitis.

The original statement that ganciclovir is active against HSV, VZV and CMV is also broadly correct. However, its most important clinical indication is CMV infection, and it is not routinely preferred for uncomplicated HSV or VZV infections because of its toxicity.

The original association between ribavirin and hepatitis C is historically correct. However, modern hepatitis C treatment primarily uses direct-acting antivirals, with ribavirin reserved for selected circumstances.

The original association between ribavirin and RSV is correct but requires qualification. Ribavirin is not routinely used for uncomplicated RSV bronchiolitis and is mainly considered in selected high-risk or severely immunocompromised patients.

The original association between ribavirin and Lassa fever reflects historical and selected clinical use, but the supporting evidence remains uncertain and specialist management is required.

38. Important Clinical Associations

Herpes Simplex Virus

HSV causes oral herpes, genital herpes, keratitis and encephalitis. Aciclovir or valaciclovir is commonly used for susceptible mucocutaneous infections, while intravenous aciclovir is essential for suspected HSV encephalitis.

Varicella-Zoster Virus

VZV causes chickenpox and shingles. Aciclovir or valaciclovir is used in selected patients, while severe disseminated infection generally requires intravenous aciclovir.

Cytomegalovirus

CMV can cause retinitis, colitis, pneumonitis and other invasive infections in immunocompromised patients. Ganciclovir or valganciclovir is commonly used for treatment or prophylaxis.

Hepatitis C Virus

Hepatitis C is now treated primarily with direct-acting antiviral combinations, such as sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Ribavirin is reserved for selected regimens.

Respiratory Syncytial Virus

RSV commonly causes bronchiolitis in infants. Supportive care is the mainstay of treatment, while ribavirin is considered only in selected clinical circumstances.

Influenza Virus

Influenza A and B may be treated with neuraminidase inhibitors such as oseltamivir or, in appropriate patients, baloxavir.

Hepatitis B Virus

Chronic hepatitis B may require long-term antiviral suppression with medications such as tenofovir or entecavir.

Key Clinical Pattern

The most important antiviral drug associations are:

Aciclovir → HSV and VZV. It is especially important for herpes simplex encephalitis, severe HSV infection and selected VZV infections.

Ganciclovir → CMV. It is particularly important for CMV retinitis and CMV disease in transplant recipients.

Valganciclovir → Oral treatment or prophylaxis of CMV in appropriate patients.

Ribavirin → Historical hepatitis C treatment, selected RSV infections and historical or selected use in Lassa fever.

Oseltamivir → Influenza A and B.

Tenofovir or entecavir → Chronic hepatitis B.

Direct-acting antivirals → Hepatitis C.

Foscarnet → Selected aciclovir-resistant HSV or ganciclovir-resistant CMV infections.

The highest-yield adverse-effect associations are aciclovir with nephrotoxicity, ganciclovir with bone marrow suppression, foscarnet with nephrotoxicity and electrolyte disturbances, and ribavirin with haemolytic anaemia and teratogenicity.

For examinations, the three original drugs can be remembered as aciclovir for herpes simplex and varicella-zoster, ganciclovir for cytomegalovirus, and ribavirin for selected RNA viral infections, while recognising that modern antiviral treatment has changed substantially, particularly for hepatitis C and RSV.


Image description
0 Comments